oncolytic virus therapies

Vyriad, Inc. Raises $29.5M Led by Renowned Genetics Entrepreneur

  (Rochester MN) — -May 17, 2022 — Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced $29.5M in new funding led by Mr. Harry Stine of Stine Seed Farms, Inc., with participation from existing investors. Stine Seed Farms joins Mayo Clinic, Mirae Asset, Regeneron Pharmaceuticals Inc., Southeast Minnesota Capital Fund (SMCF), and several high-net-worth individuals on the Vyriad investment